

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/811,361	03/16/2001	Catherine Guenther	R-125	7726

7590 10/23/2002

DELTAGEN, INC.  
ATTN: JOHN E. BURKE, ESQ.  
1003 HAMILTON AVENUE  
MENLO PARK, CA 94025

EXAMINER

QIAN, CELINE X

ART UNIT	PAPER NUMBER
----------	--------------

1636



DATE MAILED: 10/23/2002

15

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED  
OCT 31 2002  
BY: *R*

RECEIVED  
JAN 29 2003  
TECH CENTER 1600/2003

 		Application No. 09/811,361	Applicant(s) GUENTHER, CATHERINE
		Examiner Celine X Qian	Art Unit 1636

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE \_\_\_\_ MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 18 July 2002.
- 2a) ☒ This action is **FINAL**.      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 11-16 and 25-50 is/are pending in the application.
- 4a) Of the above claim(s) 11-16 and 25-37 is/are withdrawn from consideration.
- 5) ☒ Claim(s) 49 is/are allowed.
- 6) ☒ Claim(s) 38-48, 50 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
 If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) ☐ All b) ☐ Some \* c) ☐ None of:  
 1. ☐ Certified copies of the priority documents have been received.  
 2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.  
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
 \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
 a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

- |   |   |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                            | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). ____   |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)        | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____ | 6) <input type="checkbox"/> Other:  |

RECEIVED  
 JAN 29 2003  
 TECH CENTER 1600/2900

Art Unit: 1636



### DETAILED ACTION

Claims 11-16 and 25-50 are pending in the application.

Claims 11-16 and 25-37 are withdrawn from consideration as directed to non-elected subject matter.

This Office Action is in response to the Amendment filed on 7/18/02.

#### *Response to Amendment*

The rejection of claims 8 and 17-23 under 35 U.S.C. 112, first paragraph has been withdrawn in light of Applicants' cancellation of the claims.

The rejection of claims 1-4, 9, 10 and 24 under 35 U.S.C. 112, second paragraph has been withdrawn in light of Applicants' cancellation of the claims.

The rejection of claims 1-8 and 10 under 35 U.S.C. 103 (a) has been withdrawn in light of Applicants' cancellation of the claims.

The newly added claims 42-48 are rejected under 35 U.S.C. 112, first paragraph as discussed below.

The newly added claims 38-41 and 50 are rejected under 35 U.S.C. 103 (a) as discussed below.

#### *New Grounds of Rejection Necessitated by Applicants' Amendment*

##### *Claim Rejections - 35 USC § 112*

Claims 42-48 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a homozygous retina-specific nuclear receptor gene knockout mouse that **lacks production of functional retina-specific nuclear receptor protein**, a method of

Art Unit: 1636

making said mouse by introducing the knockout construct into embryonic stem (ES) cells, selecting ES cells comprising retina-specific nuclear receptor knockout construct, introducing said ES cells into blastocyst, and subsequently producing a transgenic knockout mouse, does not reasonably provide enablement for a transgenic mouse comprising any type of retina-specific nuclear receptor protein, and a method of making said knockout mouse by introducing the knockout construct into any type of cell, or introducing ES cells directly into the pseudopregnant mouse. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

The nature of the invention is a transgenic mouse comprising a disruption in a retina-specific nuclear receptor gene and exhibits phenotype comprising retinal dysplasia; and a method of making said transgenic mouse. The specification discloses a method for generating said mouse by homologous recombination using a retina-specific nuclear receptor-targeting construct (see page 54-60, examples 1-4). The specification further discloses that the homozygous knockout mice exhibit the phenotype comprising retinal dysplasia (see page 59-60, lines 30-36 and line 5-9).

When considering the predictability of this invention, one has to remember that many of the phenotypes examined in transgenic knockout models are influenced by the genetic background in which they are studied and the effect of allelic variation and the interaction between the allelic variants (pg. 1425, col. 1 1<sup>st</sup> paragraph, Sigmund, C.D. 2000. Arterioscler Thromb Vasc Biol. 20:1425-1429). The specification discloses the phenotype of a homozygous retina-specific nuclear receptor knockout mouse as exhibiting an eye abnormality. And the

Art Unit: 1636

phenotype of a retina-specific nuclear receptor knockout mouse is essential for the use of said mouse.

The specification discloses that the word "disruption" comprises alter or replace a promoter, enhancer, or splice site of a target gene, and can alter the normal gene product by inhibiting its production partially or completely or by enhancing the normal product's activity (see page 5, lines 24-27). However, it is not known in the prior art that such "disruption," would produce the phenotype as disclosed by the specification. The specification only discloses a mouse with two alleles of retina-specific nuclear receptor gene disrupted by inserting a selection marker, and said mouse exhibits the phenotype comprising retinal dysplasia. Thus, the phenotype of a transgenic mouse comprising a "disruption," as defined by the specification, in a retina-specific nuclear receptor gene is unpredictable. Thus, the specification, in the instant case, is not enabling for transgenic knockout mice that exhibit no phenotype or that exhibit transgene-dependent phenotypes other than that disclosed in the instant specification. One skilled in the art would have to engage in undue amount of experimentation to make and use the invention commensurate in scope with these claims.

The specification teaches a method of making the retina-specific nuclear receptor knockout mouse by introducing the knockout construct into embryonic stem (ES) cells, selecting ES cells comprising retina-specific nuclear receptor knockout construct, introducing said ES cells into blastocyst, introducing the blastocyst into a pseudopregnant mouse, and subsequently generates a transgenic knockout mouse. However, the specification does not support a method of making said mouse by introducing the knockout construct into any type of cells (claim 36). In addition, the specification does not support such method as to introducing ES cells directly into a

Art Unit: 1636

pseudopregnant mouse (claim 31). The prior art does not teach such methods either. Therefore, one skilled in the art would have to engage in undue amount of experimentation to make and use the invention commensurate in scope with these claims.

This rejection may be overcome by amending the claims to recite only the transgenic knockout mouse that lacks production of functional retina-specific nuclear receptor and exhibits the disclosed phenotype, recite ES cells in claim 42, and provide additional method steps in claim 43.

***Claim Rejections - 35 USC § 103***

Claims 38-41 and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mansour et al (1988, Nature, vol. 336, No. 24, 348-352), in view of Chen et al. (1999, PNAS, vol. 96, no.26, 15149-15154).

The claims are drawn to a retina-specific nuclear receptor gene-targeting construct and a method of making said construct. The claims are further drawn to a cell comprising a disruption in a retina-specific nuclear receptor gene. The recitation of "wherein the target construct when...exhibits eye abnormality" defines the intended use of the knockout construct, which does not carry patentable weight.

Mansour et al. teach a strategy for targeted disruption of the *hprt* and proto-oncogene *int-2* in mice embryonic stem cells and subsequent generation of knockout mice. Their teaching addresses the previous technical difficulty of obtaining embryonic stem cell carrying non-selectable, targeted gene mutation at loci of interest, and therefore provides a model which can be used to produce homozygous mutation of any gene, regardless of its function, if a cloned

Art Unit: 1636

fragment of the gene is available (see page 348, second paragraph, line 1-3, third paragraph, line 1-5, and page 352, fourth paragraph, line 1-3). Mansour et al. further teach the generation of two targeting constructs, pRV9.1/TK and pINT-2-N/TK, each contains two sequences from hprt and int-2 respectively, and a neo selection marker in between the two sequences (see page 350, figure 3). However, Mansour et al. do not teach how to make a retina-specific nuclear receptor gene target construct and knockout mouse.

Chen et al. teach the cloning of human and mouse retina-specific nuclear receptor gene, hRNR and mRNR. They provide the cloned coding sequence for retina-specific nuclear receptor gene (see page 15149, 2<sup>nd</sup> col., bottom part, Genbank accession numbers). Chen et al. also teach that RNR is a transcriptional repressor that interacts with the promoter of CRALBP, a protein that is involved in visual cycle (see page 15153, 2<sup>nd</sup> col., 3<sup>rd</sup> paragraph). Chen et al. further teach that RNR is the first retina specific nuclear receptor identified that could regulate visual cycle (see page 15153, 2<sup>nd</sup> col., 3<sup>rd</sup> paragraph).

It would have been obvious to one in the ordinary art at the time of invention to make a retina-specific nuclear receptor knockout mouse because Mansour et al. teach a general method of targeted gene disruption in mice based on homologous recombination using a cloned fragment of a desired gene, and Chen et al. teach the coding sequence of the mouse retina-specific nuclear receptor gene, and also teach the importance of this gene in regulating visual cycle. The ordinary artisan would have been motivated to knockout the retina-specific nuclear receptor gene in a mouse to study the role this gene plays in regulating visual cycle and its potential of being a therapeutic target in retinitis pigmentosa, as suggested by the teaching of Chen et al. (see page 15153, 2<sup>nd</sup> col., 3<sup>rd</sup> paragraph, page 15154, 1<sup>st</sup> col., 1<sup>st</sup> paragraph). Absent any evidence to

Art Unit: 1636

contrary, there would have been reasonable expectation of success in combined teaching of Mansour et al. and Chen et al. Therefore, the invention would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made.

*Conclusion*

Claim 49 is allowed.

Claims 38-48 and 50 are rejected.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

This application contains claims drawn to an invention nonelected with traverse in Paper No. 11. A complete reply to the final rejection must include cancelation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the date of this final action.




Art Unit: 1636

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 703-306-0283. The examiner can normally be reached on 9:00-5:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Remy Yucel can be reached on 703-305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are 703-305-3014 for regular communications and 703-305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Celine Qian, Ph.D.  
October 21, 2002



TERRY MCKELVEY  
PRIMARY EXAMINER